---
layout: default
title: Anagrelide
parent: 僅模型預測 (L5)
nav_order: 30
evidence_level: L5
indication_count: 2
---

# Anagrelide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ANAGRELIDE: Drug Repurposing Evaluation Report

## One-Sentence Summary

Anagrelide is a phosphodiesterase III inhibitor primarily used for the treatment of essential thrombocythemia by reducing elevated platelet counts. Currently, the TxGNN model has **no predicted new indications** for this drug, and critical data gaps remain in mechanism of action details and regulatory safety information.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Essential thrombocythemia (platelet reduction) |
| Predicted New Indication | None (no TxGNN predictions available) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no new indication predicted |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any repurposing predictions for Anagrelide. Without a predicted new indication, a mechanistic plausibility assessment cannot be performed at this time.

From existing medical knowledge, Anagrelide is a phosphodiesterase III (PDE III) inhibitor that works by inhibiting megakaryocyte maturation and reducing platelet production. It is primarily indicated for essential thrombocythemia and other myeloproliferative disorders associated with elevated platelet counts. Detailed mechanism of action data was not available in the evidence pack (DrugBank MOA field was not populated).

Further data enrichment — particularly MOA details and TxGNN model re-evaluation — would be required before any repurposing candidates can be assessed.

## Clinical Trial Evidence

Currently no related clinical trials registered for any predicted new indication, as no TxGNN prediction is available.

## Literature Evidence

Currently no related literature available for any predicted new indication, as no TxGNN prediction is available.

## Taiwan Market Information

Anagrelide is **not currently marketed in Taiwan**. No TFDA authorizations were found (0 licenses on record).

## Safety Considerations

> Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN-predicted new indications exist for Anagrelide at this time. Combined with the absence of Taiwan market authorization and multiple critical data gaps (MOA, TFDA package insert warnings/contraindications), there is insufficient information to move forward with a repurposing evaluation.

**To proceed, the following is needed:**
- **TxGNN model re-run** to generate repurposing predictions for Anagrelide (DB00261)
- **Mechanism of action (MOA)** data enrichment via DrugBank API (Data Gap DG002, severity: High)
- **TFDA package insert** warnings and contraindications extraction (Data Gap DG001, severity: Blocking)
- **Drug-drug interaction (DDI)** profiling from authoritative sources
- Assessment of whether the drug has regulatory approval in other major markets (e.g., FDA, EMA) to inform potential Taiwan regulatory pathway
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

